**Supplementary Material**

**TABLE S1** Summary of protocol deviations

| **Protocol deviation categorisation** | **Number of protocol deviations** |
|---|---|
| Bloods/urine | 94 |
| General | 1 |
| IMP | 1 |
| Inclusion/exclusion criteria | 6 |
| Laboratory | 21 |
| Lung function | 47 |
| Patient choice/health | 84 |
| Prohibited medications | 14 |
| Spirometry | 365 |
| Vital Signs | 9 |
| 6MWT | 5 |
| Questionnaires | 12 |
| **Total** | **659** |

The majority of deviations pertaining to spirometry and lung function were a consequence of sites failing to perform tests within 1 hour of the time of spirometry/lung function performed at baseline.

**TABLE S2** – Unadjusted mixed effects model for FVC change

| | Coef. | Std. Err. | z | P>\|z\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| baseFVC | 0.999 | 0.022 | 46.1 | 0.000 | 0.957 | 1.042 |
| Week 2 | -0.040 | 0.048 | -0.8 | 0.412 | -0.134 | 0.055 |
| Week 4 | 0.009 | 0.049 | 0.2 | 0.852 | -0.087 | 0.106 |
| Week 8 | -0.065 | 0.049 | -1.3 | 0.184 | -0.162 | 0.031 |
| Week 12 | 0.056 | 0.050 | 1.1 | 0.258 | -0.041 | 0.153 |
| Week 16 | 0.004 | 0.050 | 0.1 | 0.930 | -0.093 | 0.101 |
| Week 20 | 0.038 | 0.050 | 0.8 | 0.445 | -0.059 | 0.135 |
| Week 24 | 0.112 | 0.049 | 2.3 | 0.022 | 0.017 | 0.208 |
| Week 48 | 0.154 | 0.050 | 3.1 | 0.002 | 0.056 | 0.251 |
| Rituximab#Week 0 | -0.017 | 0.057 | -0.3 | 0.767 | -0.128 | 0.095 |
| Rituximab#Week 2 | 0.009 | 0.058 | 0.2 | 0.871 | -0.103 | 0.122 |
| Rituximab#Week 4 | -0.083 | 0.059 | -1.4 | 0.159 | -0.198 | 0.032 |
| Rituximab#Week 8 | 0.073 | 0.059 | 1.2 | 0.215 | -0.042 | 0.188 |
| Rituximab#Week 12 | -0.076 | 0.059 | -1.3 | 0.201 | -0.191 | 0.040 |
| Rituximab#Week 16 | -0.021 | 0.059 | -0.3 | 0.728 | -0.137 | 0.096 |
| Rituximab#Week 20 | -0.039 | 0.060 | -0.6 | 0.518 | -0.157 | 0.079 |
| Rituximab#Week 24 | -0.038 | 0.059 | -0.6 | 0.518 | -0.155 | 0.078 |
| Rituximab#Week 48 | -0.057 | 0.063 | -0.9 | 0.363 | -0.180 | 0.066 |

| | | | | | | |
|---|---|---|---|---|---|---|
| _cons | 0.063 | 0.077 | 0.8 | 0.413 | -0.088 | 0.215 |

**TABLE S3** – Fixed effects model adjusted to baseline for FVC

| | Coef. | Std. Err. | t | P>\|t\| | [95% Conf. Interval] | |
|---|---|---|---|---|---|---|
| baseFVC | 0.989 | 0.013 | 78.5 | 0.000 | 0.965 | 1.014 |
| | | | | | | |
| Week 2 | -0.038 | 0.059 | -0.6 | 0.523 | -0.155 | 0.079 |
| Week 4 | -0.002 | 0.060 | -0.0 | 0.970 | -0.121 | 0.116 |
| Week 8 | -0.090 | 0.060 | -1.5 | 0.138 | -0.208 | 0.029 |
| Week 12 | 0.041 | 0.061 | 0.7 | 0.505 | -0.079 | 0.160 |
| Week 16 | -0.009 | 0.061 | -0.1 | 0.882 | -0.128 | 0.110 |
| Week 20 | 0.024 | 0.061 | 0.4 | 0.688 | -0.095 | 0.144 |
| Week 24 | 0.099 | 0.060 | 1.6 | 0.100 | -0.019 | 0.217 |
| Week 48 | 0.138 | 0.061 | 2.3 | 0.024 | 0.018 | 0.259 |
| | | | | | | |
| Rituximab#Week 0 | 0.000 | 0.059 | 0.0 | 0.994 | -0.115 | 0.116 |
| Rituximab#Week 2 | 0.026 | 0.060 | 0.4 | 0.667 | -0.092 | 0.143 |
| Rituximab#Week 4 | -0.062 | 0.061 | -1.0 | 0.310 | -0.183 | 0.058 |
| Rituximab#Week 8 | 0.118 | 0.061 | 1.9 | 0.055 | -0.003 | 0.238 |
| Rituximab#Week 12 | -0.041 | 0.062 | -0.7 | 0.505 | -0.162 | 0.080 |
| Rituximab#Week 16 | 0.012 | 0.062 | 0.2 | 0.848 | -0.110 | 0.134 |
| Rituximab#Week 20 | -0.005 | 0.063 | -0.1 | 0.933 | -0.129 | 0.119 |
| Rituximab#Week 24 | -0.002 | 0.062 | -0.0 | 0.976 | -0.124 | 0.120 |

| | | | | | | |
|---|---|---|---|---|---|---|
| Rituximab#Week 48 | -0.024 | 0.067 | -0.4 | 0.715 | -0.155 | 0.106 |
| _cons | 0.023 | 0.050 | 0.5 | 0.642 | -0.075 | 0.122 |

**TABLE S4** – Unadjusted fixed effects model for FVC change

| | Coef. | Std. Err. | t | P>\|t\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| Week 2 | -0.024 | 0.177 | -0.1 | 0.894 | -0.371 | 0.324 |
| Week 4 | 0.022 | 0.180 | 0.1 | 0.903 | -0.331 | 0.375 |
| Week 8 | -0.042 | 0.180 | -0.2 | 0.816 | -0.395 | 0.312 |
| Week 12 | 0.097 | 0.181 | 0.5 | 0.591 | -0.258 | 0.453 |
| Week 16 | 0.018 | 0.181 | 0.1 | 0.921 | -0.338 | 0.374 |
| Week 20 | 0.052 | 0.181 | 0.3 | 0.776 | -0.304 | 0.407 |
| Week 24 | 0.124 | 0.179 | 0.7 | 0.489 | -0.227 | 0.475 |
| Week 48 | 0.216 | 0.182 | 1.2 | 0.236 | -0.142 | 0.574 |
| Rituximab#Week 0 | 0.044 | 0.175 | 0.3 | 0.802 | -0.300 | 0.388 |
| Rituximab#Week 2 | 0.058 | 0.178 | 0.3 | 0.742 | -0.291 | 0.408 |
| Rituximab#Week 4 | -0.026 | 0.183 | -0.1 | 0.889 | -0.384 | 0.333 |
| Rituximab#Week 8 | 0.134 | 0.183 | 0.7 | 0.465 | -0.225 | 0.493 |
| Rituximab#Week 12 | -0.026 | 0.184 | -0.1 | 0.886 | -0.387 | 0.335 |
| Rituximab#Week 16 | 0.044 | 0.185 | 0.2 | 0.813 | -0.319 | 0.407 |
| Rituximab#Week 20 | 0.043 | 0.188 | 0.2 | 0.818 | -0.326 | 0.412 |
| Rituximab#Week 24 | 0.027 | 0.185 | 0.1 | 0.884 | -0.336 | 0.390 |
| Rituximab#Week 48 | 0.072 | 0.198 | 0.4 | 0.717 | -0.318 | 0.461 |

| | | | | | | |
|---|---|---|---|---|---|---|
| _cons | 2.206 | 0.124 | 17.8 | 0.000 | 1.963 | 2.449 |

**FIGURE S1 –** Boxplot of observed FVC values (in litres) by visit




**TABLE S5** – Adjusted mixed effects model with removal of one outlier value. Pt 89 (Cyclophosphamide) had a 3.46 folds increase at week 4 (results: W0: 1.4 ; W2: 1.56; W4 4.85; there were no more measurements).The second highest increase was 2.45 fold for patient 40, week 8 (Rituximab).Pt 89's Week 4 measurement was omitted in the sensitivity analysis below using the same model as for the primary outcome.

| | Coef. | Std. Err. | z | P>\|z\| | [95% Conf. Interval] |
|---|---|---|---|---|---|
| baseFVC | 1.003 | 0.020 | 49.4 | 0.000 | 0.963 | 1.042 |

| | | | | | | |
|---|---|---|---|---|---|---|
| Week 2 | -0.040 | 0.043 | -0.9 | 0.359 | -0.124 | 0.045 |
| Week 4 | -0.067 | 0.044 | -1.5 | 0.133 | -0.153 | 0.020 |
| Week 8 | -0.080 | 0.044 | -1.8 | 0.069 | -0.166 | 0.006 |
| Week 12 | 0.041 | 0.044 | 0.9 | 0.353 | -0.046 | 0.128 |
| Week 16 | -0.010 | 0.044 | -0.2 | 0.814 | -0.097 | 0.076 |
| Week 20 | 0.023 | 0.044 | 0.5 | 0.603 | -0.064 | 0.110 |
| Week 24 | 0.098 | 0.044 | 2.2 | 0.026 | 0.012 | 0.183 |
| Week 48 | 0.139 | 0.045 | 3.1 | 0.002 | 0.051 | 0.226 |
| | | | | | | |
| Rituximab#Week 0 | -0.008 | 0.052 | -0.1 | 0.884 | -0.109 | 0.094 |
| Rituximab#Week 2 | 0.019 | 0.052 | 0.4 | 0.718 | -0.084 | 0.121 |
| Rituximab#Week 4 | 0.001 | 0.054 | 0.0 | 0.984 | -0.104 | 0.106 |
| Rituximab#Week 8 | 0.097 | 0.053 | 1.8 | 0.069 | -0.008 | 0.202 |
| Rituximab#Week 12 | -0.052 | 0.054 | -1.0 | 0.337 | -0.157 | 0.054 |
| Rituximab#Week 16 | 0.003 | 0.054 | 0.1 | 0.949 | -0.102 | 0.109 |
| Rituximab#Week 20 | -0.015 | 0.055 | -0.3 | 0.787 | -0.122 | 0.092 |
| Rituximab#Week 24 | -0.014 | 0.054 | -0.3 | 0.789 | -0.120 | 0.091 |
| Rituximab#Week 48 | -0.034 | 0.057 | -0.6 | 0.553 | -0.145 | 0.078 |
| | | | | | | |
| _cons | 0.038 | 0.065 | 0.6 | 0.559 | -0.089 | 0.165 |

**TABLE S6** – Unadjusted mixed effects model for DLco

| | Coef. | Std. Err. | z | P>\|z\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| baseDLCO | 1.024 | 0.035 | 29.7 | 0.000 | 0.957 | 1.092 |
| Week 12 | -0.037 | 0.096 | -0.4 | 0.703 | -0.225 | 0.152 |
| Week 24 | 0.058 | 0.092 | 0.6 | 0.530 | -0.123 | 0.239 |
| Week 48 | 0.134 | 0.097 | 1.4 | 0.167 | -0.056 | 0.324 |
| Rituximab#Week 0 | -0.003 | 0.121 | -0.0 | 0.982 | -0.240 | 0.235 |
| Rituximab#Week 12 | 0.111 | 0.127 | 0.9 | 0.383 | -0.139 | 0.361 |
| Rituximab#Week 24 | 0.183 | 0.127 | 1.4 | 0.149 | -0.065 | 0.431 |
| Rituximab#Week 48 | 0.116 | 0.134 | 0.9 | 0.388 | -0.147 | 0.379 |
| _cons | -0.082 | 0.144 | -0.6 | 0.570 | -0.363 | 0.200 |

**TABLE S7** – Unadjusted fixed effects model for DLco

| ITMPFTLCO | Coef. | Std. Err. | t | P>\|t\| | [95% Conf. Interval] | |
|---|---|---|---|---|---|---|
| Week 12 | 0.061 | 0.327 | 0.2 | 0.852 | -0.583 | 0.705 |
| Week 24 | 0.060 | 0.318 | 0.2 | 0.850 | -0.565 | 0.685 |
| Week 48 | 0.208 | 0.330 | 0.6 | 0.529 | -0.441 | 0.856 |
| Rituximab#Week 0 | 0.115 | 0.320 | 0.4 | 0.720 | -0.514 | 0.744 |
| Rituximab#Week 12 | 0.100 | 0.331 | 0.3 | 0.763 | -0.551 | 0.751 |
| Rituximab#Week 24 | 0.179 | 0.325 | 0.5 | 0.583 | -0.461 | 0.819 |
| Rituximab#Week 48 | 0.220 | 0.356 | 0.6 | 0.536 | -0.479 | 0.920 |
| _cons | 3.348 | 0.225 | 14.9 | 0.000 | 2.905 | 3.790 |

**TABLE S8** – Unadjusted mixed effects model for EQ5D

| EQ5D_score | Coef. | Std. Err. | z | P>\|z\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| baseQLQ_EQ5D | 0.76 | 0.05 | 15.5 | 0.000 | 0.66 | 0.85 |
| Week 24 | 4.02 | 2.93 | 1.4 | 0.169 | -1.71 | 9.76 |
| Week 48 | -0.65 | 2.99 | -0.2 | 0.828 | -6.50 | 5.21 |
| Rituximab#Week 0 | 0.42 | 2.95 | 0.1 | 0.888 | -5.36 | 6.20 |
| Rituximab#Week 24 | 3.17 | 3.17 | 1.0 | 0.318 | -3.05 | 9.39 |
| Rituximab#Week 48 | 4.98 | 3.36 | 1.5 | 0.138 | -1.61 | 11.57 |
| _cons | 13.61 | 3.47 | 3.9 | 0.000 | 6.82 | 20.41 |

**TABLE S9** – Unadjusted fixed effects model for EQ5D

| EQ5D_score | Coef. | Std. Err. | t | P>\|t\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| Week 24 | 7.42 | 4.35 | 1.7 | 0.089 | -1.14 | 15.98 |
| Week 48 | 2.84 | 4.42 | 0.6 | 0.521 | -5.87 | 11.55 |
| Rituximab#Week 0 | 2.83 | 4.25 | 0.7 | 0.507 | -5.55 | 11.20 |
| Rituximab#Week 24 | 3.68 | 4.53 | 0.8 | 0.418 | -5.25 | 12.60 |
| Rituximab#Week 48 | 3.96 | 4.79 | 0.8 | 0.409 | -5.47 | 13.40 |
| _cons | 55.27 | 2.99 | 18.5 | 0.000 | 49.38 | 61.17 |

**TABLE S10** – Unadjusted mixed effects model for global disease activity score (GDAS)

| GDAS_score | Coef. | Std. Err. | z | P>\|z\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| baseQLQ_GDAS | 0.60 | 0.06 | 9.8 | 0.000 | 0.48 | 0.72 |
| Week 24 | -2.89 | 0.34 | -8.5 | 0.000 | -3.55 | -2.22 |
| Week 48 | -2.78 | 0.35 | -7.9 | 0.000 | -3.47 | -2.09 |
| Rituximab#Week 0 | -0.18 | 0.35 | -0.5 | 0.613 | -0.86 | 0.51 |
| Rituximab#Week 24 | -0.12 | 0.36 | -0.3 | 0.751 | -0.83 | 0.60 |
| Rituximab#Week 48 | 0.91 | 0.40 | 2.2 | 0.025 | 0.12 | 1.70 |
| _cons | 1.99 | 0.39 | 5.1 | 0.000 | 1.22 | 2.76 |

**TABLE S11** – Unadjusted fixed effects model for global disease activity score (GDAS)

| GDAS_score | Coef. | Std. Err. | t | P>\|t\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| Week 24 | -2.72 | 0.44 | -6.2 | 0.000 | -3.59 | -1.85 |
| Week 48 | -2.63 | 0.46 | -5.7 | 0.000 | -3.54 | -1.72 |
| | | | | | | |
| Rituximab#Week 0 | -0.45 | 0.44 | -1.0 | 0.317 | -1.32 | 0.43 |
| Rituximab#Week 24 | -0.44 | 0.44 | -1.0 | 0.328 | -1.31 | 0.44 |
| Rituximab#Week 48 | 0.34 | 0.50 | 0.7 | 0.494 | -0.64 | 1.32 |
| | | | | | | |
| _cons | 5.03 | 0.31 | 16.2 | 0.000 | 4.41 | 5.64 |

**Table S12** – Unadjusted mixed effects model for KB-ILD

| KBILD_Total | Coef. | Std. Err. | z | P>\|z\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| baseQLQ_KBILD | 0.74 | 0.05 | 14.0 | 0.000 | 0.64 | 0.85 |
| r | | | | | | |
| Week 24 | 9.56 | 2.80 | 3.4 | 0.001 | 4.07 | 15.04 |
| Week 48 | 5.79 | 2.84 | 2.0 | 0.041 | 0.22 | 11.35 |
| | | | | | | |
| Rituximab#Week 0 | 1.31 | 3.08 | 0.4 | 0.671 | -4.72 | 7.33 |
| Rituximab#Week 24 | 0.50 | 3.24 | 0.2 | 0.877 | -5.84 | 6.84 |
| Rituximab#Week 48 | 1.39 | 3.42 | 0.4 | 0.685 | -5.31 | 8.08 |
| | | | | | | |
| _cons | 11.77 | 3.26 | 3.6 | 0.000 | 5.38 | 18.16 |

**TABLE S13** – Unadjusted fixed effects model for KB-ILD.

| KBILD_Total | Coef. | Std. Err. | t | P>\|t\| | [95% Conf. Interval] | |
|---|---|---|---|---|---|---|
| Week 24 | 10.33 | 4.46 | 2.3 | 0.021 | 1.55 | 19.12 |
| Week 48 | 7.01 | 4.51 | 1.6 | 0.122 | -1.88 | 15.90 |
| | | | | | | |
| Rituximab#Week 0 | 5.10 | 4.39 | 1.2 | 0.246 | -3.54 | 13.74 |
| Rituximab#Week 24 | 3.05 | 4.61 | 0.7 | 0.508 | -6.02 | 12.13 |
| Rituximab#Week 48 | 1.50 | 4.88 | 0.3 | 0.759 | -8.11 | 11.11 |
| | | | | | | |
| _cons | 45.94 | 3.09 | 14.9 | 0.000 | 39.86 | 52.02 |

**TABLE S14 –** Unadjusted mixed-effects model for SGRQ

| SGRQ_score | COEF. | STD. ERR. | Z | P>\|Z\| | [95% CONF. INTERVAL] | |
|---|---|---|---|---|---|---|
| baseQLQ_SGRQ | 0.84 | 0.06 | 13.5 | 0.000 | 0.72 | 0.97 |
| | | | | | | |
| order | | | | | | |
| Week 24 | -4.94 | 2.66 | -1.9 | 0.064 | -10.16 | 0.28 |
| Week 48 | -6.67 | 2.71 | -2.5 | 0.014 | -11.97 | -1.36 |
| | | | | | | |
| Arm#order | | | | | | |
| Rituximab#Week 0 | -0.64 | 3.10 | -0.2 | 0.836 | -6.72 | 5.44 |
| Rituximab#Week 24 | 0.67 | 3.28 | 0.2 | 0.838 | -5.76 | 7.11 |
| Rituximab#Week 48 | 2.68 | 3.40 | 0.8 | 0.430 | -3.98 | 9.35 |
| | | | | | | |
| _cons | 8.74 | 4.12 | 2.1 | 0.034 | 0.67 | 16.81 |

**TABLE S15** - Unadjusted fixed effects model for SGRQ

| SGRQ_score | COEF. | STD. ERR. | T | P>\|T\| | [95% CONF. | INTERVAL] |
|---|---|---|---|---|---|---|
| order | | | | | | |
| Week 24 | -7.03 | 4.59 | -1.5 | 0.127 | -16.06 | 2.01 |
| Week 48 | -7.62 | 4.64 | -1.6 | 0.102 | -16.76 | 1.52 |
| | | | | | | |
| Arm#order | | | | | | |
| Rituximab#Week 0 | -4.12 | 4.56 | -0.9 | 0.367 | -13.10 | 4.86 |
| Rituximab#Week 24 | -3.45 | 4.75 | -0.7 | 0.468 | -12.80 | 5.90 |
| Rituximab#Week 48 | -1.78 | 4.97 | -0.4 | 0.720 | -11.56 | 8.00 |
| | | | | | | |
| _cons | 56.19 | 3.19 | 17.6 | 0.000 | 49.91 | 62.47 |

**TABLE S16** – Unadjusted mixed effects model for mRss

| mRSS_score | Coef. | Std. Err. | z | P>\|z\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| baseQLQ_mRSS | 0.87 | 0.07 | 12.8 | 0.000 | 0.73 | 1.00 |
| r | | | | | | |
| Week 12 | 3.27 | 1.27 | 2.6 | 0.010 | 0.79 | 5.75 |
| Week 24 | 1.21 | 1.22 | 1.0 | 0.320 | -1.18 | 3.59 |
| Week 48 | -0.11 | 1.24 | -0.1 | 0.930 | -2.54 | 2.32 |
| | | | | | | |
| Rituximab#Week 0 | 0.29 | 1.48 | 0.2 | 0.846 | -2.61 | 3.18 |
| Rituximab#Week 12 | -3.83 | 1.63 | -2.4 | 0.018 | -7.02 | -0.64 |
| Rituximab#Week 24 | -3.69 | 1.64 | -2.3 | 0.024 | -6.90 | -0.49 |
| Rituximab#Week 48 | -3.10 | 1.80 | -1.7 | 0.085 | -6.62 | 0.43 |
| | | | | | | |
| _cons | 0.95 | 1.06 | 0.9 | 0.372 | -1.13 | 3.03 |

**TABLE S17** – Unadjusted fixed effects model for mRss

| mRSS_score | Coef. | Std. Err. | t | P>\|t\| | [95% Conf. | Interval] |
|---|---|---|---|---|---|---|
| Week 12 | 2.98 | 2.66 | 1.1 | 0.266 | -2.29 | 8.24 |
| Week 24 | 2.13 | 2.58 | 0.8 | 0.411 | -2.97 | 7.23 |
| Week 48 | -1.08 | 2.58 | -0.4 | 0.675 | -6.19 | 4.02 |
| Rituximab#Week 0 | 2.15 | 2.66 | 0.8 | 0.420 | -3.11 | 7.42 |
| Rituximab#Week 12 | -2.00 | 2.84 | -0.7 | 0.482 | -7.62 | 3.62 |
| Rituximab#Week 24 | -2.09 | 2.85 | -0.7 | 0.466 | -7.72 | 3.55 |
| Rituximab#Week 48 | 0.67 | 3.10 | 0.2 | 0.830 | -5.46 | 6.79 |
| _cons | 7.08 | 1.71 | 4.1 | 0.000 | 3.69 | 10.47 |

**Lab safety results**

**TABLE S18** – subjects, by visit, with white blood cell count below the lower limit of normal.

| **Subject** | **Visit** | **White cell count (x10*9/l)** | **Treatment** |
|---|---|---|---|
| 44 | Week 24 | 3.5 | Cyclophosphamide |
| 58 | Screening | 3.8 | Cyclophosphamide |
| 58 | Week 2 | 2.9 | Cyclophosphamide |
| 58 | Week 4 | 3.7 | Cyclophosphamide |
| 58 | Week 8 | 3.5 | Cyclophosphamide |
| 58 | Week 16 | 3.8 | Cyclophosphamide |
| 58 | Week 24 | 3.5 | Cyclophosphamide |
| 58 | Week 48 | 3.7 | Cyclophosphamide |
| 74 | Screening | 2.5 | Rituximab |
| 74 | Week 0 | 2.1 | Rituximab |
| 74 | Week 2 | 2.1 | Rituximab |
| 74 | Week 4 | 2.8 | Rituximab |
| 74 | Week 8 | 3.5 | Rituximab |
| 74 | Week 12 | 2.7 | Rituximab |
| 74 | Week 16 | 2.9 | Rituximab |
| 74 | Week 20 | 2.8 | Rituximab |
| 74 | Week 24 | 3.2 | Rituximab |
| 74 | Week 48 | 3.2 | Rituximab |
| 92 | Week 0 | 3.7 | Rituximab |
| 97 | Week 2 | 3.6 | Cyclophosphamide |

| Subject | Visit | White cell count (x10*9/l) | Treatment |
|---|---|---|---|
| 103 | Screening | 3.9 | Rituximab |
| 103 | Week 12 | 3.1 | Rituximab |
| 103 | Week 16 | 3.7 | Rituximab |

**TABLE S19** – subjects, by visit, with neutrophil count below the lower limit of normal.

| Subject | Visit | Neutrophil count (x10*9/l) | Treatment |
|---|---|---|---|
| 74 | Week 0 | 1.2 | Rituximab |
| 74 | Week 2 | 1.3 | Rituximab |

**TABLE S20** – subjects, by visit, with creatinine level above the upper limit of normal.

| **Subject** | **Visit** | **Creatinine *(µmol/L)*** | **Treatment** |
|---|---|---|---|
| 24 | Week 16 | 122 | Cyclophosphamide |
| 49 | Week 4 | 124 | Rituximab |
| 49 | Week 12 | 121 | Rituximab |
| 49 | Week 24 | 127 | Rituximab |
| 82 | Week 20 | 127 | Cyclophosphamide |
| 84 | Screening | 143 | Cyclophosphamide |
| 84 | Week 0 | 143 | Cyclophosphamide |
| 84 | Week 2 | 159 | Cyclophosphamide |
| 84 | Week 4 | 165 | Cyclophosphamide |
| 84 | Week 8 | 150 | Cyclophosphamide |
| 93 | Week 20 | 121 | Cyclophosphamide |
| 100 | Week 0 | 123 | Cyclophosphamide |

**TABLE S21 –** subjects, by visit, with a rise in creatinine from baseline.

| **Subject** | **Visit** | **Creatinine *(µmol/L)*** | **Baseline creatinine *(µmol/L)*** | **Treatment** |
|---|---|---|---|---|
| 16 | Week 24 | 85 | 56 | Rituximab |
| 36 | Week 12 | 53 | 35 | Rituximab |
| 36 | Week 16 | 57 | 35 | Rituximab |
| 60 | Week 20 | 56 | 37 | Rituximab |
| 96 | Week 2 | 115 | 59 | Rituximab |
| 98 | Week 16 | 86 | 53 | Cyclophosphamide |
| 98 | Week 24 | 83 | 53 | Cyclophosphamide |

**TABLE S22** – subjects, by visit, with alanine aminotransferase level above the upper limit of normal.

| Subject | Visit | ALT (U/L) | Treatment |
|---|---|---|---|
| 3 | Screening | 85 | Cyclophosphamide |
| 19 | Week 0 | 99 | Rituximab |
| 21 | Screening | 99 | Rituximab |
| 28 | Week 4 | 85 | Cyclophosphamide |
| 32 | Week 16 | 97 | Cyclophosphamide |
| 36 | Screening | 99 | Rituximab |
| 44 | Week 8 | 86 | Cyclophosphamide |
| 44 | Unscheduled | 99 | Cyclophosphamide |
| 49 | Week 0 | 89 | Rituximab |
| 49 | Week 4 | 88 | Rituximab |
| 49 | Week 8 | 87 | Rituximab |
| 49 | Week 24 | 82 | Rituximab |
| 55 | Screening | 92 | Cyclophosphamide |
| 80 | Screening | 90 | Cyclophosphamide |
| 81 | Week 12 | 99 | Cyclophosphamide |
| 89 | Screening | 93 | Cyclophosphamide |

**TABLE S23** – subjects, by visit, with alkaline phosphatase level above the upper limit of normal.

| Subject | Visit | ALP (U/L) | Treatment |
|---|---|---|---|
| 82 | Unscheduled | 283 | Cyclophosphamide |